-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FDqv0D695GllHKmM/nmvE58/JFINLgBL9k2OrN8z/AQ45k2t1B0dDW/K0wTJrWME p3v3U2opBZXt6HrHMgU6hQ== 0000000000-08-032790.txt : 20080818 0000000000-08-032790.hdr.sgml : 20080818 20080702143301 ACCESSION NUMBER: 0000000000-08-032790 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080702 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: OSIRIS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001360886 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 710881115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 443-545-1819 MAIL ADDRESS: STREET 1: 7015 ALBERT EINSTEIN DRIVE CITY: COLUMBIA STATE: MD ZIP: 21046 LETTER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@.3DT M,2]/(#@O12`U.#(P+TX@,2]4(#DW-S4O2"!;(#4U-B`Q-C-=/CX-96YD;V)J M#2`@("`@("`@("`@("`@("`@("`@("`@#0IXF4@ M,3DO4')E=B`Y-S8U+U)O;W0@-R`P(%(O26YF;R`U(#`@4B])1%L\13-$-T4U M-D$S1CDS-4%%03(X-D%$,#`P0C`R-S(R13<^/#0W-3DQ13DU,38T,39$-#4X M0T0P,T8U.#A#03!#,34R/ET^/@T*7!E+U!A9V4^/@UE;F1O8FH-.2`P(&]B:CP\+T-O;&]R4W!A8V4\/"]# M'1'4W1A=&4\/"]'4S$@,3<@,"!2/CX^/@UE M;F1O8FH-,3`@,"!O8FH\/"]3=6)T>7!E+U1R=654>7!E+T9O;G1$97-CM7S&DA%39#?=KJ+8V=Q1;)-HBU[:'8 M`RO3,0M&\I)T$__['9*R9'L3-RBP\D$S8\S3S)O'`2]^7\3PH(,/57!150G$ M4*V".`&*/WR5%"991LH"JL>`PD.0D'220U6C4ST%(4!4?4=[G$(UL[$:8UTH M)G%NHSY0O7N300FE=&)QQGOS*?@:?A8,KEFMQ6,T)7DH)`?6+.$OLB!PRX2$ MZ._JH\L?:G/QA6DW4-"8PINJ^%^?CUNY@V0$":53^\6+*UU`K3W7H.LF2*8D M0]+H0)OE?-R%SS#JN(H'VF+'P!6!>Z2)2;@54NH1W*W)C!SE9$-.YJF^4UR+ M)6^BG&2A09J=L82KM>`KF#_S>FO$#PZ?5BM191 M1B:ABFP7(7/.)J*D##GBU<['"O]H:H(?+,-CW*&UV"DBG%"DXE)^X\K`7#3: M<-'`3-G"SK=WU] MPE$Q(!7NWQEG"D=#O`C?'ZR'+.^WQ@'0P>HX[:G3%$3C-"]R,@V_<%@SG'G= M/FXD-]AANU6@^`_!GZ!=P0Y=1U!7*;%I8;95!E=B*^\EJ8`;,&@5D.C'P:&R/!CFGR-Y( MB%_)O:X643+)8]L'&MD$>6ILA(:U]:?H\[VAG.'\/$5?[C-V/F/D7\=U_&Q_ MIP.YZ='$_'M"C_W#^'Y5\M5*\1W<"[Z4ITOF5.0OP/_*7!E+U1R=654>7!E+T9O M;G1$97-C513=Q;'?V_)GI"5L,-C#5N`L`:0 M-6QAD1T$40A)"`$20DC8!4%$!11%1(2JE3+6;71&3T6=+JYCK0[6?>K2`_4P MZN@XM!;7CIT7.$>=3F>FT^\?[_=\P"@)Z6JM=4P"P"-UJ#/ M2HS%%A448J0)``,*(`(1`#)YK2XM.R$'X)+&2[!:W`G\BYY>!Y!IO2),RL`P M\/^)+=?I#0!`&3@'*)2U:65)H91$^OQ!'&V-+%JGKWG M?.8YVL0*C5:!LREGG4*C,/%IG%?7&94X(ZDX=]6IE?4X7\79I/\W!2K M4F"@T5(PE*>NKE`:#,$,FKY3I%9BD6J.3:1L!F+_SG#BFVF)XD8-%H<'! M0G\?T3N%^J^;OU"FWL[3D\RYGD'\"V]M/^=7/0J`>!:OS?JWMM(M`(RO!,#R MYEN;R_L`,/&^';[XSGWXIGDI-QAT8;Z^]?7U/FJEW,=4T#?ZGPZ_0.^\S\=T MW)OR8''*,IFQRH"9ZB:OKJHVZK%:G4RNQ(0_'>)?'?CS>7AG*J46C\C# MITRM5>'MUBK4!G6U%E-K_U,3?V783S0_U[BX8Z\!K]@'L"[R`/*W"P#ET@!2 MM`W?@=[T+962!S+P-=_AWOS M;`+#8#L8`[O!?G`0C(./P0GP1W`>?`FN@5M@$DR#AV`&/`6O(`@B00R("UE! M#I`KY`7Y0V(H$HJ'4J$LJ``J@520%C)"+=`*J`?JAX:A'=!NZ/?04>@$=`ZZ M!'T%34$/H.^@ES`"TV$>;`>[P;ZP&(Z!4^`<>`FL@FO@)K@37@E&!I%19#]R##F+7$$F MD4?("Y2(@6=0F?0UP0&P9;@10@C M2`F+""I"/:&+,$C82?B(<(9PC3!->$HD$OE$`3&$F$0L(%80FXF]Q*W$`\3C MQ$O$N\19$HED1?(B19#223*2@=1%VD+:1_J,=)DT37I.II$=R/[D!'(A64ON M(`^2]Y`_)5\FWR._HK`HKI0P2CI%06FD]%'&*,IMZA,:C>9$"Z5ETM2TY;0AVN]HG].F:"_H'+HG74(OHAOIZ^@? MTH_3OZ(_83`8;HQH1B'#P%C'V,TXQ?B:\=R,:^9C)C53F+69C9@=-KML]IA) M8;HR8YA+F4W,0>8AYD7F(Q:%Y<:2L&2L5M8(ZRCK!FN6S66+V.EL#;N7O8=] MCGV?0^*X<>(Y"DXGYP/.*:1^0)>%)>!:^']UO> M!&_&G&,>:)YGWF`^8OZ)^20?X;OQI?PJ?A__(/\Z_Z6%G46,A=)BC<5^B\L6 MSRQM+*,ME9;=E@NMMUF?L7YDP[,) MMY';=-LWQ>Z4W2-[OGVT?87]@/VG M]@\OZS$W@EN^VRFW< M[;[`4B`5-`GV"FZ[,]RCW&O<1]VO>A`]Q!Z5'EL]OO2$/8,\RSU'/"]ZP5[! M7FJOK5Z7O`G>H=Y:[U'O&T*Z,$98)]PKG/+A^Z3Z=/B,^SSV=?$M]-W@>];W MM5^07Y7?F-\M$4>4+.H0'1-]Y^_I+_R$WQ#QQAKA7_'DH(30VM"WTX]`7 M8<%AAK"#87\/%X97AN\)O[]`L$"Y8&S!W0BG"%G$CHC)2"RR)/+]R,DHQRA9 MU&C4-]'.T8KHG='W8CQB*F+VQ3R.]8O5QWX4^TP2)EDF.1Z'Q"7&=<=-Q'/B M<^.'X[].<$I0)>Q-F$D,2FQ./)Y$2$I)VI!T0VHGE4MW2V>20Y*7)9].H:=D MIPRG?)/JF:I//98&IR6G;4R[O=!UH7;A>#I(EZ9O3+^3(J"(X6DPKS"G86SB^,7;UH\7114U%5T?8E@2<.26419 M?]E]581JH^I!>53Y8/DCM40]K/ZV(JEB>\6SRO3*#RM_K,JO.J`A:THT1[4< M;:7V=+5]=4/U)9V7KDLW61-6LZEF1I^BWUD+U2ZI/6+@X3]3%XSNQI7&J;K( MNI&ZY_5Y]8<:V`W:A@N-GHUK&N\U)33]IAEMEC>?;'%L:6^96A:S;$K+-N:VS;7IYXO)=[=3VRO8_=?AU]'=\OR)_Q;%.N\[EG7=7)J[^Z ML2I\U?;5Z&KUZHDU`6NVK'G=K>C^HL>O9[#GAUYY[Q=K16N'UOZXKFS=1%]P MW[;UQ/7:]==9)W2GD">KI\=GXN?^J!I MH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJ MCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/%$ MXIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'M MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G' M^E?ZY_MW_`?\F/TI_;K^2_[<_VW__P(,`/>$\_L*#0IE;F1S=')E86T-96YD M;V)J#3$U(#`@;V)J/#PO4W1E;58@.#(O1F]N=$YA;64O5&EM97-.97=2;VUA M;E!3350O1F]N=%-T%LM-38X("TS,#<@,C`P,"`Q,#`W M72]!7!E+T9O;G1$97-C7!E+U!A9V5S+TMI9'-;."`P(%)=/CX-96YD;V)J#30@,"!O8FH\/"]3=6)T M>7!E+UA-3"],96YG=&@@,S4T,"]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_ M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z M>&UP=&L](C,N,2TW,#$B/@H@("`\"UN&%P.D-R96%T;W)4 M;V]L/@H@("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`P."TP-RTP,E0Q-#HS M,#HU,RTP-#HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@(#PO&%P34TZ26YS M=&%N8V5)1#YU=6ED.F8V-#5E8F8U+3=B.60M-#&%P34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I M;VX^"B`@(#PO')E9@T*,"`V#0HP,#`P,#`P,#`P(#8U-3,U(&8-"C`P,#`P,#4X,C`@,#`P M,#`@;@T*,#`P,#`P-3@U,R`P,#`P,"!N#0HP,#`P,#`U.# -----END PRIVACY-ENHANCED MESSAGE-----